KR910000124A - 실질적으로 수불용성인 약제학적 활성 성분을 위한 약제학적 수성 현탁액 - Google Patents
실질적으로 수불용성인 약제학적 활성 성분을 위한 약제학적 수성 현탁액 Download PDFInfo
- Publication number
- KR910000124A KR910000124A KR1019900009449A KR900009449A KR910000124A KR 910000124 A KR910000124 A KR 910000124A KR 1019900009449 A KR1019900009449 A KR 1019900009449A KR 900009449 A KR900009449 A KR 900009449A KR 910000124 A KR910000124 A KR 910000124A
- Authority
- KR
- South Korea
- Prior art keywords
- suspension
- composition
- mixture
- xanthan gum
- pregelatinized starch
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (21)
- 실질적으로 수불용성 약제학적 활성성분 약 0.2 내지 20.0% ; 잔탄검, 예비젤라틴화 전분 및 폴리옥시에틸렌 소르비탄 모노올리에이트의 현탁 안정화 유효량 ; 당, 다가의 감미 알코올, 글리세린, 인공 감미료, 향미제 및 이의 혼합물로 이루어진 그룹중에서 선택된 풍미은폐 조성물의 유효량 ; 및 물을 포함함을 특징으로 하는, 수성의 약제학적 현탁 조성물.
- 제1항에 있어서, 잔탄검, 예비젤라틴화 전분 및 폴리옥시에틸렌 소르비탄 모노올리에이트의 현탁액 안정화 유효량이 총 형탁액의 약 1.25 내지 1.90%(w/v)인 조성물.
- 제1항에 있어서, 잔탄검이 총 현탁액의 약 0.13 내지 0.24%(w/v)이고, 예비젤라틴화 전분이 총 현탁액의 약 1.05 내지 1.60%(w/v)이며, 폴리옥시에틸렌 소르비탄 모노올리에이트가 총 현탁액의 약 0.01 내지 1.00%(w/v)인 조성물.
- 제1항에 있어서, 풍미은폐 조성물이 총 현탁액의 약 25% 내지 50%(w/v)조성물.
- 제1항에 있어서, 풍미은폐 조성물이 총 현탁액의 슈크로스 약 20 내지 35%(w/v), 솔비톨 약 0 내지 약 10%(w/v) 및 글리세린 약 5 내지 약 30%(w/v)를 포함하는 조성물.
- 제1항에 있어서, 용액의 pH를 3.5 내지 5.0으로 안정화시키는 양으로 구연산을 현탁액에 첨가한 조성물.
- (a) 총 현탁액의 잔탄 검 약 0.13 내지 0.24%(w/v), 예비 젤라틴화 전분 약 1.05 내지 1.60%(w/v) 및 당 약 4 내지 7%(w/v)를 무수 블렌딩시키고 ; (b) 별도로, 총 현탁액의 물 약 50%(w/v), 글리세린 5 내지 30%(w/v) 및 다가 감미 알코올, 0 내지 10%(w/v)를 혼합하며; (c) 단계(a)의 무수 블렌드를 단계 (b)의 수성 혼합물에 가한 후, 잔탄검 및 예비 젤라틴화 전분이 혼합물중에 균질하게 분산될 때 까지 혼합하고; (d) 총 현탁액의 당 약 16 내지 28%(w/v)를 단계 (c)의 분산액에 가한 후, 혼합물중의 성분이 균질하게 분산될 때까지 혼합하며; (e) 총 현탁약의 폴리옥시에틸렌 소르비탄 모노올리에이트 약 0.01 내지 1.00%(w/v) 및 실질적으로 수불용성의 약제학적 활성성분 0.1 내지 약 20.0%(w/v)를 성분이 혼합물중에서 균질하게 분산될 때까지 단계 (d)의 혼합물과 혼합한 후 ; (f) 100% 목적 용량의 약제학적 수성 현탁액을 제조하기 위해 충분한 물과 단계 (e)의 혼합물을 혼합함을 특징으로 하여, 수성의 약제학적 현탁 조성물을 제조하는 방법.
- 제7항에 있어서, 용액의 pH를 약 3.5 내지 5.0으로 안정화시키는데 충분한 구연산 및 유효량의 보존재를 단계 (e)의 혼합물에 첨가하는 방법.
- 제7항에 있어서, 단계(f)의 현탁액을 탈기시킨 후, 물을 첨가하여 현탁액의 용얄을 100% 조정하는 방법.
- 제7항에 있어서, 단계 (a) 및 (d)의 당이 슈크로스이고 ; 단계(d)의 다가 감미 알코올이 솔비톨이며 ; 향미제 및 착색 성분을 단계 (e)의 혼합물에 첨가하는 방법.
- 이부프로펜 약 0.4 내지 20.0% ; 잔탄검, 예비 젤라틴화 전분 및 폴리옥시에틸렌 소르비탄 모노올리 에이트의 현탁 안정화 유효량 ; 당, 다가의 감미 알코올, 글리세린, 인공감미료, 향미제 및 이의 혼합물로 이루어진 그룹중에서 선택된 풍미은폐 조성물의 유효량 ; 현탁액의 pH를 약 3.5 내지 5.0의 범위로 유지시키는 유효량의 구연산 ; 및 물을 포함하는 것을 특징으로 하는 수성의 이부프로펜 현탁 조성물.
- 제11항에 있어서, 잔탄검, 예비젤라틴화 전분 및 폴리옥시에틸렌 소르비탄 모노올리에이트의 현탁 안정화 유효량이 총 현탁액의 약 1.25 내지 1.90%(w/v)인 조성물.
- 제11항에 있어서, 잔탄검이 총 현탁액의 약 0.13 내지 0.24%(w/v)이고, 예비젤라틴화 전분이 총 현탁액의 약 1.05 내지 1.60%(w/v)이며, 폴리옥시에틸렌 소르비탄 모노올리에이트가 총 현탁액의 약 0.01 내지 1.00%(w/v)인 조성물.
- 제11항에 있어서, 풍미은폐 조성물이 총 현탁액의 약 25 내지 50%(w/v)인 조성물.
- 제11항에 있어서, 풍미은폐 조성물이 총 현탁액의 슈크로스 약 20 내지 35%(w/v), 솔비톨 약 0 내지 약 10%(w/v) 및 글리세린 약 5 내지 약 30%(w/v)를 포함하는 조성물.
- (a) 총 현탁액의 잔탄검 약 0.13 내지 약 0.24%(w/v), 예비젤라틴화 전분 약 1.05 내지 1.60%(w/v) 및 슈크로스 약 4 내지 7%(w/v)를 무수 블렌딩시키고 ; (b) 별도로, 총 현탁액의 물 약 50%(w/v), 글리세린 5 내지 30%(w/v) 및 솔비톨 0 내지 10%(w/v)를 혼합하며 ; (c) 단계 (a)의 무수 블렌드를 단계 (b)의 수성 혼합물에 가한후, 잔탄검 및 예비 젤라틴화 전분이 혼합물중에 균질하게 분산될 때까지 혼합하고 ; (d) 총 현탁액의 슈크로스 약 16 내지 28%(w/v)를 단계 (c)의 분산액에 가한후, 혼합물중의 성분이 균질하게 분산될때까지 혼합하며 ; (e) 총 현탁액의 폴리옥시에틸렌 소르비탄 모노올리에이트 약 0.01 내지 1.00%(w/v) 및 이부프로펜 0.4 내지 10.0%(w/v), 유효량의 보존제와 용액의 pH를 약 3.5 내지 5.0으로 안정화시키는데 충분한 구연산을 성분이 혼합물중에서 균질하게 분산 될 때까지 단계 (d)의 혼합물과 혼합한후 ; (f) 100% 목적 용량의 약제학적 수성 현탁액을 제조하기 위해 충분한 물과 단계 (e)의 혼합물을 혼합함을 특징으로 하여, 수성의 이부프로펜 현탁 조성물을 제조하는 방법.
- 제16항에 있어서, 단계 (f)의 현탁액을 탈기시킨후, 물을 첨가하여 현탁액의 용량을 100%로 조정하는 방법.
- 제16항에 있어서, 향미제 및 착색제 성분을 단계 (e) 혼합물에 첨가하는 방법.
- 총 현탁액의 이부프로펜 약 0.4 내지 10.0%(w/v), 잔탄검 약 0.13 내지 0.24%(w/v), 예비젤라틴화 전분 약 1.05 내지 1.60%(w/v) 및 폴리옥시에틸렌 소르비탄 모노올리에이트 약 0.01 내지 1.00%(w/v) ; 총 현탁액의 슈크로스 약 20 내지 35%(w/v) 및 솔비톨 약 0 내지 10%(w/v) ; 총 현탁액의 글리세린 약 5 내지 30%(w/v) ; 현탁액의 pH를 약 3.5 내지 5.0의 범위로 유지시키기에 효과적인 양의 구연산을 포함함을 특징으로 하는 수성의 이부프로펜 현탁 조성물.
- 제19항에 있어서, 총 현탁액의 이부프로펜 약 2.0%(w/v), 잔탄검 0.18%(w/v), 예비젤라틴화 전분 1.31%(w/v) 및 폴리옥시에틸렌 소르비탄 모노 올리에이트 0.05%(w/v)를 함유하는 현탁액.
- ※참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37273489A | 1989-06-28 | 1989-06-28 | |
US372,734 | 1989-06-28 | ||
US372734 | 1989-06-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR910000124A true KR910000124A (ko) | 1991-01-29 |
KR0161969B1 KR0161969B1 (ko) | 1998-12-01 |
Family
ID=23469412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019900009449A KR0161969B1 (ko) | 1989-06-28 | 1990-06-26 | 실질적으로 수불용성인 약제학적 활성 성분을 위한 약제학적 수성 현탁액 조성물 |
Country Status (17)
Country | Link |
---|---|
US (2) | US5374659A (ko) |
EP (1) | EP0405930B1 (ko) |
JP (1) | JP2874967B2 (ko) |
KR (1) | KR0161969B1 (ko) |
AT (1) | ATE110259T1 (ko) |
AU (1) | AU635283B2 (ko) |
CA (1) | CA2019863C (ko) |
DE (1) | DE69011766T2 (ko) |
ES (1) | ES2064634T3 (ko) |
GR (1) | GR1002094B (ko) |
GT (1) | GT199000066A (ko) |
HK (1) | HK127494A (ko) |
IE (1) | IE64400B1 (ko) |
IL (1) | IL94887A (ko) |
NZ (1) | NZ234143A (ko) |
PT (1) | PT94504B (ko) |
ZA (1) | ZA905058B (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101452721B1 (ko) * | 2006-05-19 | 2014-10-21 | 노르브룩 래보러토리 리미티드 | 안정한 수성현탁액 |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0662320T3 (da) * | 1991-08-30 | 2001-09-24 | Showa Pharm Chem Ind | Tør gelsammensætning |
US5605930A (en) * | 1991-10-21 | 1997-02-25 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for treating and preventing pathologies including cancer |
EP0620001A1 (en) * | 1993-04-16 | 1994-10-19 | McNEIL-PPC, INC. | Aqueous pharmaceutical suspension and process for preparation thereof |
FR2713931B1 (fr) * | 1993-12-20 | 1996-04-05 | Laurence Paris | Nouvelles compositions pharmaceutiques liquides à base d'ibuprofène et leur procédé de préparation. |
NZ272574A (en) * | 1995-07-14 | 1999-02-25 | Lilly Eli & Co Nz Ltd | Aqueous base suspension concentrate containing at least one ionophore antibiotic and wetting agent and/or a surfactant and xanthan gum optionally with a suspension agent, an antifreeze agent and an antifoaming agent; drench for veterinary treatment |
WO1997003650A1 (en) * | 1995-07-14 | 1997-02-06 | Eli Lilly & Company (Nz) Limited | Ionophore antibiotic formulations |
NZ280384A (en) | 1995-11-02 | 1997-01-29 | Lilly Eli & Co Nz Ltd | Animal feed supplement comprising a wettable powder composition of an ionophore antibiotic |
AUPN862596A0 (en) * | 1996-03-12 | 1996-04-04 | F.H. Faulding & Co. Limited | Pharmaceutical compositions |
CN1220598A (zh) * | 1996-05-02 | 1999-06-23 | 大正制药株式会社 | 水难溶性酸性药物的悬浮液 |
US5712310A (en) * | 1996-06-14 | 1998-01-27 | Alpharma Uspd, Inc. | Suspension of substantially water-insoluble drugs and methods of their manufacture |
US20110189348A1 (en) * | 1998-10-28 | 2011-08-04 | San-Ei Gen F.F.I., Inc. | Compositions containing sucralose and application thereof |
US7229658B1 (en) * | 1998-10-28 | 2007-06-12 | San-Ei Gen F.F.I., Inc | Compositions containing sucralose and application thereof |
USH2044H1 (en) | 1998-11-02 | 2002-09-03 | Mcneil-Ppc, Inc. | Container with retaining member |
BR0009557A (pt) | 1999-04-06 | 2002-05-28 | Ethypharm Lab Prod Ethiques | Suspensão farmacêutica para beber de ibuprofeno |
US6211246B1 (en) * | 1999-06-10 | 2001-04-03 | Mcneil-Ppc, Inc. | Rapidly absorbed liquid compositions |
US6726922B1 (en) | 1999-06-28 | 2004-04-27 | Minu, L.L.C. | Process and composition for temporarily suppressing pain |
WO2001091585A2 (en) | 2000-05-31 | 2001-12-06 | Pepsico, Inc. | Low-staining orange food coloring composition |
WO2002010756A2 (en) * | 2000-08-02 | 2002-02-07 | Malope Company Limited | Diagnosis and treatment of non-ulcer dyspepsia based on hypothalamic-pituitary-adrenal axis abnormality |
JP4204864B2 (ja) * | 2000-12-25 | 2009-01-07 | ライオン株式会社 | 懸濁液の安定化方法及び安定化された懸濁液 |
DE60120630T2 (de) * | 2001-02-14 | 2007-05-24 | Forte Iq B.V. | Pharmazeutische Zusammensetzung enthaltend Xanthangummi |
BR0207930A (pt) * | 2001-03-05 | 2004-03-02 | Ortho Mcneil Pharm Inc | Composições farmacêuticas lìquidas com sabor mascarado |
BR0208626A (pt) * | 2001-04-03 | 2004-03-09 | Schering Corp | Composição antifúngica com biodisponibilidade intensificada |
CA2455939C (en) * | 2001-07-31 | 2011-03-22 | Wyeth Llc | Sucralose formulations to mask unpleasant tastes |
US6770263B1 (en) * | 2001-10-01 | 2004-08-03 | Naturewell, Incorporated | Compositions and methods for the treatment of aches and pains |
US20040132823A1 (en) * | 2001-11-02 | 2004-07-08 | Leo Pavliv | Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid |
ES2197781B1 (es) * | 2001-12-04 | 2005-02-16 | Farmalider, S.A. | Composiciones farmaceuticas liquidas de base acuosa en forma de suspension para la administracion por via oral de ibuprofeno. |
US6998480B2 (en) | 2002-03-08 | 2006-02-14 | Tate & Lyle Public Limited Company | Process for improving sucralose purity and yield |
US7049435B2 (en) | 2002-03-08 | 2006-05-23 | Tate & Lyle Public Limited Company | Extractive methods for purifying sucralose |
US7300670B2 (en) | 2002-04-03 | 2007-11-27 | Unilab Pharmatech, Ltd. | Oral suspension formulation |
US20030232097A1 (en) * | 2002-06-17 | 2003-12-18 | Strides Inc. | Oily wax matrix suspension formulation comprising ibuprofen free acid and potassium salt of ibuprofen |
ATE541562T1 (de) * | 2002-06-17 | 2012-02-15 | Taro Pharmaceuticals Usa Inc | Ibuprofen-suspension |
KR100509432B1 (ko) * | 2002-12-13 | 2005-08-22 | 주식회사 동구제약 | S(+)-이부프로펜을 함유한 시럽제 조성물 및 그의 제조방법 |
US20040253311A1 (en) * | 2002-12-18 | 2004-12-16 | Roger Berlin | Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines |
CL2003002653A1 (es) * | 2002-12-18 | 2005-04-22 | Wyeth Corp | Composicion farmaceutica que comprende (a) un antiinflamatorio no esteroidal (nsaid), preferentemente ibuprofeno, (b) un descongestionante, preferentemente pseudoefedrina y (c) un antihistaminico, preferentemente clorfeniramina; metodo para su prepar |
US20040186180A1 (en) * | 2003-03-21 | 2004-09-23 | Gelotte Cathy K. | Non-steroidal anti-inflammatory drug dosing regimen |
WO2005025622A1 (ja) * | 2003-09-12 | 2005-03-24 | Ryukakusan Co. Ltd. | 苦みマスキング粒状ゼリー飲料 |
US20050069590A1 (en) * | 2003-09-30 | 2005-03-31 | Buehler Gail K. | Stable suspensions for medicinal dosages |
US20050095299A1 (en) * | 2003-10-30 | 2005-05-05 | Wynn David W. | Controlled release analgesic suspensions |
US20050095300A1 (en) * | 2003-10-30 | 2005-05-05 | Wynn David W. | Controlled release analgesic suspensions |
US20060088587A1 (en) * | 2004-10-27 | 2006-04-27 | Bunick Frank J | Dosage forms having a microreliefed surface and methods and apparatus for their production |
US20070281022A1 (en) * | 2004-10-27 | 2007-12-06 | Bunick Frank J | Dosage forms having a microreliefed surface and methods and apparatus for their production |
US20070190133A1 (en) * | 2004-10-27 | 2007-08-16 | Bunick Frank J | Dosage forms having a microreliefed surface and methods and apparatus for their production |
US20060088593A1 (en) * | 2004-10-27 | 2006-04-27 | Bunick Frank J | Dosage forms having a microreliefed surface and methods and apparatus for their production |
US20060088586A1 (en) * | 2004-10-27 | 2006-04-27 | Bunick Frank J | Dosage forms having a microreliefed surface and methods and apparatus for their production |
US8383159B2 (en) * | 2004-10-27 | 2013-02-26 | Mcneil-Ppc, Inc. | Dosage forms having a microreliefed surface and methods and apparatus for their production |
US20060087051A1 (en) * | 2004-10-27 | 2006-04-27 | Bunick Frank J | Dosage forms having a microreliefed surface and methods and apparatus for their production |
US20060093630A1 (en) * | 2004-10-29 | 2006-05-04 | Buehler Gail K | Dye-free pharmaceutical suspensions and related methods |
US20060093631A1 (en) * | 2004-10-29 | 2006-05-04 | Buehler Gail K | Dye-free pharmaceutical suspensions and related methods |
US20060093629A1 (en) | 2004-10-29 | 2006-05-04 | Buehler Gail K | Dye-free pharmaceutical suspensions and related methods |
US20060094760A1 (en) * | 2004-11-04 | 2006-05-04 | Fawzy Abdel A | Composition, system and method of treatment of gastrointestinal disorders with nizatidine oral solution |
US7611695B2 (en) * | 2004-11-15 | 2009-11-03 | Ultradent Products, Inc. | Flavored hemostatic and acid etching compositions |
PT2522365T (pt) | 2004-11-24 | 2017-02-08 | Meda Pharmaceuticals Inc | Composições que compreendem azelastina e seus métodos de utilização |
US20070020330A1 (en) | 2004-11-24 | 2007-01-25 | Medpointe Healthcare Inc. | Compositions comprising azelastine and methods of use thereof |
US8758816B2 (en) * | 2004-11-24 | 2014-06-24 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
PT1824493E (pt) * | 2004-12-06 | 2008-11-18 | Janssen Pharmaceutica Nv | Suspensão oral que compreende meloxicam |
CN101400343B (zh) | 2006-03-16 | 2012-01-11 | 特瑞斯制药股份有限公司 | 含有药物-离子交换树脂复合物的经修饰释放的制剂 |
US20080014275A1 (en) * | 2006-07-13 | 2008-01-17 | Buehler Gail K | Pharmaceutical suspensions and related methods |
CN101534795B (zh) | 2006-11-21 | 2013-04-03 | 麦克内尔-Ppc股份有限公司 | 改进释放的镇痛悬浮液 |
MX2009006114A (es) * | 2007-03-02 | 2009-11-10 | Meda Pharmaceuticals Inc | Composiciones que comprenden carisoprodol y metodos de uso de las mismas. |
MX2009009337A (es) * | 2007-03-09 | 2009-09-21 | Hercules Inc | Tiosulfato de sodio estable con base en suspensiones de polimero fluidizado de hidroxietilcelulosa para servicios de yacimientos. |
US20080260837A1 (en) * | 2007-04-20 | 2008-10-23 | Qpharma, L.L.C. | Physically stable aqueous suspensions of active pharmaceuticals |
US20080268025A1 (en) * | 2007-04-25 | 2008-10-30 | Donald Spector | Compositions Useful for Preventing Pain and Soreness Resulting from Exercise and Methods of Use |
US9833510B2 (en) * | 2007-06-12 | 2017-12-05 | Johnson & Johnson Consumer Inc. | Modified release solid or semi-solid dosage forms |
WO2009085959A1 (en) | 2007-12-20 | 2009-07-09 | Organic Recovery, Llc | Methods and compositions for digestion of organic waste |
CN102006867A (zh) * | 2008-01-03 | 2011-04-06 | 沃根哈德研究中心 | 含有扑热息痛和布洛芬的口服药物混悬剂 |
US8436156B2 (en) * | 2008-01-04 | 2013-05-07 | Tate & Lyle Technology Limited | Method for the production of sucralose |
KR20100130219A (ko) * | 2008-03-20 | 2010-12-10 | 테이트 앤드 라일 테크놀러지 리미티드 | 3급 아미드 용매로부터 산을 제거하는 방법 |
US8436157B2 (en) * | 2008-03-26 | 2013-05-07 | Tate & Lyle Technology Limited | Method for the production of sucralose |
AR071134A1 (es) * | 2008-04-03 | 2010-05-26 | Tate & Lyle Technology Ltd | Cristalizacion de sucralosa a partir de chorros que contienen sucralosa |
US20090299055A1 (en) * | 2008-04-03 | 2009-12-03 | Tate & Lyle Technology Limited | Purification of Sucralose Containing Feed Streams for Sucralose Crystallization |
US20090259036A1 (en) * | 2008-04-03 | 2009-10-15 | Tate & Lyle Technology Limited | Extraction of less polar impurities from sucralose containing aqueous feed streams |
WO2009137193A2 (en) * | 2008-04-03 | 2009-11-12 | Tate & Lyte Technology Ltd | Effect of carbohydrate concentration on sucralose extraction efficiency |
US8497367B2 (en) * | 2008-04-03 | 2013-07-30 | Tate & Lyle Technology Limited | Sucralose purification process |
SG10201914059WA (en) | 2008-10-22 | 2020-03-30 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
WO2010103384A1 (en) * | 2009-03-13 | 2010-09-16 | Nucitec S.A. De C.V. | Compositions and methods for treatment and prevention of cardiovascular disease |
GB2469158B (en) | 2009-03-31 | 2011-09-28 | Peter J Seaberg | Base-assisted formation of tin-sucrose adducts |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
GB2474311B (en) * | 2009-10-12 | 2012-10-17 | Tate & Lyle Technology Ltd | Low temperature, single solvent process for the production of sucrose-6-ester |
GB2474310B (en) | 2009-10-12 | 2012-02-29 | Tate & Lyle Technology Ltd | Process for the production of sucrose-6-ester |
GB201110520D0 (en) | 2011-05-10 | 2011-08-03 | Tate & Lyle Technology Ltd | Extraction of carboxylic acids with tin compounds |
EP3139769B1 (en) | 2014-05-05 | 2022-06-22 | California Safe Soil, LLC | Nutrient rich compositions |
CN113354649A (zh) | 2014-11-16 | 2021-09-07 | 阵列生物制药公司 | 一种新的晶型 |
EP3061501A1 (en) | 2015-02-27 | 2016-08-31 | Rottapharm Ltd. | Composition for the treatment of acne |
EP3117825A1 (en) | 2015-07-16 | 2017-01-18 | Rottapharm S.p.A. | Oral formulation comprising berberine and morus alba extract |
US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
CA3003153A1 (en) | 2015-10-26 | 2017-05-04 | Loxo Oncology, Inc. | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
PE20181888A1 (es) | 2016-04-04 | 2018-12-11 | Loxo Oncology Inc | Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
RU2745953C2 (ru) | 2016-05-18 | 2021-04-05 | Локсо Онколоджи, Инк. | Способ получения (s)-n-(5-((r)-2-(2,5-дифторфенил)пирролидин-1-ил)-пиразоло[1,5-a]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамида и его солей |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
EP3677283A4 (en) * | 2017-08-31 | 2021-05-12 | Tohoku University | APPROPRIATE AREA OF OSMOTIC PRESSURE OF A SOLUTION WITH MEDICINAL PRODUCT EFFECTIVE IN LYMPHODIC DELIVERY SYSTEM |
US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
US20190247398A1 (en) * | 2017-10-26 | 2019-08-15 | Array Biopharma Inc. | Formulations of a macrocyclic trk kinase inhibitor |
GB2585825B (en) * | 2019-07-09 | 2023-03-22 | Lexon Uk Holdings Ltd | Suspending vehicle formulation |
CN112516083B (zh) * | 2020-12-15 | 2023-02-28 | 太阳升(亳州)生物医药科技有限公司 | 布洛芬混悬液及其制备方法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB971700A (en) * | 1961-02-02 | 1964-09-30 | Boots Pure Drug Co Ltd | Anti-Inflammatory Agents |
US3911128A (en) * | 1972-02-07 | 1975-10-07 | Sandoz Ag | Substituted purines as hypolipidemics |
US3852257A (en) * | 1973-02-05 | 1974-12-03 | Kelco Co | Suspension polymerization in the presence of xanthan gum |
US4447454A (en) * | 1977-04-01 | 1984-05-08 | The Upjohn Company | Analgetic compounds, compositions and process of treatment |
US4145440A (en) * | 1977-08-18 | 1979-03-20 | The Upjohn Company | Liquid suspension of an aluminum salt of ibuprofen |
CA1167403A (en) * | 1979-07-10 | 1984-05-15 | Unilever Limited | Microbial heteropolysaccharide |
US4329448A (en) * | 1979-07-10 | 1982-05-11 | Lever Brothers Company | Microbial heteropolysaccharide |
JPS5835965B2 (ja) * | 1979-07-31 | 1983-08-05 | ライオン株式会社 | 口腔用組成物 |
JPS5846483B2 (ja) * | 1979-09-20 | 1983-10-17 | ライオン株式会社 | 口腔用組成物 |
US4251560A (en) * | 1979-08-21 | 1981-02-17 | General Foods Corporation | Cream-containing frozen whipped topping composition |
US4361580A (en) * | 1980-06-20 | 1982-11-30 | The Upjohn Manufacturing Company | Aluminum ibuprofen pharmaceutical suspensions |
US4346108A (en) * | 1981-06-22 | 1982-08-24 | The Upjohn Manufacturing Company M | Method for preventing adhesion formation |
US4542158A (en) * | 1981-12-21 | 1985-09-17 | Merck & Co., Inc. | Prodrug esters of diflunisal and related compounds |
US4762709A (en) * | 1983-09-16 | 1988-08-09 | Pennwalt Corporation | Liquid prolonged release pharmaceutical formulations containing ionic constituents |
IT1183574B (it) * | 1985-05-08 | 1987-10-22 | Eurand Spa | Metodo per ottenere una sospensione estemporanea omogenea di microcapsule |
US4744986A (en) * | 1986-03-07 | 1988-05-17 | Rorer Pharmaceutical Corporation | Process for the preparation of a viscosity-stable antacid composition |
US4761274A (en) * | 1986-03-27 | 1988-08-02 | Warner-Lambert Company | Medicament adsorbates of analgesics with complex magnesium aluminum silicate and their preparation |
GB8609566D0 (en) * | 1986-04-18 | 1986-05-21 | Boots Co Plc | Analgesic method |
US4684666A (en) * | 1986-08-19 | 1987-08-04 | Haas Pharmaceuticals, Inc. | Stabilized liquid analgesic compositions |
GB8628359D0 (en) * | 1986-11-27 | 1986-12-31 | Zyma Sa | Galenical formulation |
GB8702411D0 (en) * | 1987-02-03 | 1987-03-11 | Zyma Sa | Swellable pellets |
US4788220A (en) * | 1987-07-08 | 1988-11-29 | American Home Products Corporation (Del.) | Pediatric ibuprofen compositions |
US4861797A (en) * | 1987-10-15 | 1989-08-29 | Oratech Pharmaceutical Development Corporation | Liquid ibuprofen compositions and methods of making them |
US4975465A (en) * | 1989-03-28 | 1990-12-04 | American Home Products Corporation | Orally administrable ibuprofen compositions |
-
1990
- 1990-06-19 NZ NZ234143A patent/NZ234143A/xx unknown
- 1990-06-21 GR GR900100481A patent/GR1002094B/el unknown
- 1990-06-26 CA CA002019863A patent/CA2019863C/en not_active Expired - Lifetime
- 1990-06-26 KR KR1019900009449A patent/KR0161969B1/ko not_active IP Right Cessation
- 1990-06-27 AU AU57926/90A patent/AU635283B2/en not_active Ceased
- 1990-06-27 ES ES90307001T patent/ES2064634T3/es not_active Expired - Lifetime
- 1990-06-27 EP EP90307001A patent/EP0405930B1/en not_active Expired - Lifetime
- 1990-06-27 AT AT90307001T patent/ATE110259T1/de not_active IP Right Cessation
- 1990-06-27 DE DE69011766T patent/DE69011766T2/de not_active Expired - Fee Related
- 1990-06-27 PT PT94504A patent/PT94504B/pt not_active IP Right Cessation
- 1990-06-27 IL IL9488790A patent/IL94887A/en unknown
- 1990-06-27 IE IE233290A patent/IE64400B1/en not_active IP Right Cessation
- 1990-06-27 JP JP2166964A patent/JP2874967B2/ja not_active Expired - Lifetime
- 1990-06-28 ZA ZA905058A patent/ZA905058B/xx unknown
- 1990-10-17 GT GT199000066A patent/GT199000066A/es unknown
-
1994
- 1994-03-28 US US08/219,009 patent/US5374659A/en not_active Expired - Lifetime
- 1994-09-28 US US08/314,168 patent/US5621005A/en not_active Expired - Lifetime
- 1994-11-17 HK HK127494A patent/HK127494A/xx not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101452721B1 (ko) * | 2006-05-19 | 2014-10-21 | 노르브룩 래보러토리 리미티드 | 안정한 수성현탁액 |
Also Published As
Publication number | Publication date |
---|---|
IL94887A (en) | 1994-11-11 |
IE902332A1 (en) | 1991-01-16 |
ES2064634T3 (es) | 1995-02-01 |
PT94504A (pt) | 1991-02-08 |
PT94504B (pt) | 1997-02-28 |
NZ234143A (en) | 1991-10-25 |
AU5792690A (en) | 1991-02-07 |
ATE110259T1 (de) | 1994-09-15 |
CA2019863C (en) | 1996-06-04 |
US5374659A (en) | 1994-12-20 |
US5621005A (en) | 1997-04-15 |
JP2874967B2 (ja) | 1999-03-24 |
DE69011766T2 (de) | 1994-12-22 |
GR1002094B (en) | 1995-12-28 |
GR900100481A (el) | 1991-11-15 |
EP0405930B1 (en) | 1994-08-24 |
JPH0363219A (ja) | 1991-03-19 |
GT199000066A (es) | 1992-04-09 |
IE64400B1 (en) | 1995-08-09 |
ZA905058B (en) | 1992-02-26 |
IL94887A0 (en) | 1991-04-15 |
IE902332L (en) | 1990-12-28 |
KR0161969B1 (ko) | 1998-12-01 |
AU635283B2 (en) | 1993-03-18 |
HK127494A (en) | 1994-11-25 |
CA2019863A1 (en) | 1990-12-28 |
EP0405930A3 (en) | 1991-09-04 |
DE69011766D1 (de) | 1994-09-29 |
EP0405930A2 (en) | 1991-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR910000124A (ko) | 실질적으로 수불용성인 약제학적 활성 성분을 위한 약제학적 수성 현탁액 | |
DE60014255T2 (de) | Zusammensetzung, die fettlösliche Substanzen in einer Kohlenhydratmatrix enthält | |
DE2850989C2 (de) | Verfahren zur Herstellung eines mittig gefüllten Kaugummis | |
DE60222000T2 (de) | Sprühgetrocknete zubereitungen und verfahren für deren herstellung | |
KR100249469B1 (ko) | 연 젤라틴 캡슐 껍질 조성물 | |
EP0197987B2 (de) | Verfahren zur herstellung von lösungen von umgekehrten mizellen | |
EP0835613B1 (de) | Stabile Emulsionen und Trockenpulver von Mischungen fettlöslicher Vitamine, deren Herstellung und Verwendung | |
DE69922296T2 (de) | Antibakterille zusammensetzung zur topischen anwendung, enthaltend faropenem | |
HUP9903334A2 (hu) | Eljárás morfológiailag egységes mikrokapszulák előállítására, valamint az ezzel az eljárással előállított mikrokapszulák | |
DE69933518T2 (de) | Stabile flüssige zusammensetzungen von kalzium-ascorbat und verfahren zu ihrer herstellung und verwendung | |
DE3529694A1 (de) | Gelatinekapseln und verfahren zu ihrer herstellung | |
DE4141351A1 (de) | Stabile pulverfoermige vitamin- und/oder carotinoid-praeparate und verfahren zu deren herstellung | |
JPH11514221A (ja) | 新規プロセス | |
JP2001288090A (ja) | ミノキシジル含有製剤 | |
EP0358951B1 (de) | Pulvrige, hydrophile Theophyllinformulierung und Verfahren zu ihrer Herstellung | |
CH693982A5 (de) | Cefuroximaxetil enthaltende Zusammensetzung. | |
KR900013964A (ko) | 활성형 비타민 d₃류 제제용 조성물 및 이를 함유하는 안정한 활성형 비타민 d₃류 제제의 제조방법 | |
CZ185392A3 (en) | Preparation containing megestrol-acetate | |
RU2007129728A (ru) | Композиция сиропа, включающая дексибупропен в качестве активного ингредиента, и способ ее получения | |
US5538989A (en) | Fenbendazole formulations | |
DE60029698T2 (de) | Amoxicillin und Clavulanat enthaltende pharmazeutische Formulierung | |
JPH10291928A (ja) | ソフトカプセル | |
US4769244A (en) | Non-hygroscopic water-soluble pulverulent composition for the preparation of drinks and process for its preparation | |
JP2838051B2 (ja) | 水溶性リコピン製剤 | |
JPS59127646A (ja) | W/o/w型エマルジヨンの製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20080825 Year of fee payment: 11 |
|
LAPS | Lapse due to unpaid annual fee |